Wechselwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-213931 · Präparat HOS-155234
5 Table 1: INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by Interaction Recommendations concerning therapeutic areas Geometric mean change (%) co-administration ANTI-INFECTIVES Antiretrovirals HIV NRTIs/N[t]RTIs Didanosine*# didanosine AUC ↑ 12% No dose adjustment is required. 400 mg once daily didanosine Cmin NA Didanosine should be administered at didanosine Cmax ↔ least two hours before or at least four rilpivirine AUC ↔ hours after rilpivirine. rilpivirine Cmin ↔ rilpivirine Cmax ↔ Tenofovir disoproxil *# tenofovir AUC ↑ 23% No dose adjustment is required. 245 mg once daily tenofovir Cmin ↑ 24% tenofovir Cmax ↑ 19% rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↔ Other NRTIs Not studied. No clinically relevant No dose adjustment is required. (abacavir, emtricitabine, drug-drug interactions are expected. lamivudine, stavudine and zidovudine) HIV NNRTIs NNRTIs Not studied. It is not recommended to (delavirdine, efavirenz, co-administer rilpivirine with other etravirine, nevirapine) NNRTIs. HIV PIs – with co-administration of low dose ritonavir Darunavir/ritonavir*# darunavir AUC ↔ Concomitant use of rilpivirine with 800/100 mg once daily darunavir Cmin ↓ 11% ritonavir-boosted PIs causes an darunavir Cmax ↔ increase in the plasma concentrations rilpivirine AUC ↑ 130% of rilpivirine, but no dose adjustment rilpivirine Cmin ↑ 178% is required. rilpivirine Cmax ↑ 79%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) stavudine (HOS-088080) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) darunavir (HOS-086181) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) ritonavir (HOS-084521) abacavir (HOS-088077) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage e6d1aeb7ba2f265a48a0f9e4bedfdb523c00ec0b8a0eab1f7f1643ca7f5bebb4 · Zeichen 2025–4372 im Abschnitt